AI Summary & Key Takeaways
AI InsightConclusion: It was shown that systemic inflammation parameters, including NLR, MLR and PLR, are not a reliable marker in the diagnosis and prognosis of ROP.
📌 3 Key Takeaways
Abstract
Purpose: This study compared the blood inflammatory parameters between early preterm infants with retinopathy of prematurity (ROP) who were treated with intravitreal anti-vascular endothelial growth factor (VEGF)) and those who did not need treatment. Materials and Methods: One hundred and six infants were included in the study. Early preterm infants with a gestational age (GA) ≤ 32 weeks and birth weight (BW) ≤ 1500 gm were included. These infants were divided into three groups: infants without ROP (group 1), infants with ROP who did not require treatment (group 2) and infants with ROP who were treated with intravitreal anti-VEGF (group 3). In the first week, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR) of the groups were calculated and compared. Results: Of 106 infants, 38 (35.8%) were in group 1, 30 (28.3%) were in group 2 and 38 (35.8%) were in group 3. GA was 24.89 ± 1.48 weeks, and BW was significantly lower in group 3, 775.21 ± 175.11 gm. (p < 0.001). There was no significant difference between the groups in terms of NLR, MLR and PLR (p = 0.833, p = 0.918 and p = 0.082, respectively). Logistic regression analysis was performed; BW was a statistically significant independent risk factor (OR: 0,999 %CI: 0,992-0,999 p = 0.022) associated with ROP that required treatment. Conclusion: It was shown that systemic inflammation parameters, including NLR, MLR and PLR, are not a reliable marker in the diagnosis and prognosis of ROP.